Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic Transplantation.
Tim 3
cytokines
graft-vs.-host disease
hematopoietic stem cell transplantation
sIL2-Rα
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
09
2019
accepted:
31
12
2019
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Assays of cytokines in the plasma at the onset of graft-vs. -host disease (GVHD) can predict disease severity and treatment-related mortality (TRM); however, the optimal time during which cytokines should be tested and the specific panel of cytokines with the highest predictive ability remain unknown. We chose a predefined time point, 18 days after hematopoietic stem cell transplantation (HSCT), to measure the levels of six cytokines in the plasma: soluble interleukin-2 receptor alpha (sIL2-Rα), T-cell immunoglobulin domain and mucin domain-3 (TIM-3), suppression of tumorigenicity-2 (ST-2), intercellular adhesion molecule (ICAM-1), interferon-gamma (IFN-γ), and interleukin-6 (IL-6). The study included 95 patients, who underwent allogeneic hematopoietic transplantation at our institution. Plasma levels of sIL2-Rα and TIM-3, measured as continuous data, had predictive value for overall survival (sIL2-Rα,
Identifiants
pubmed: 32117211
doi: 10.3389/fimmu.2019.03158
pmc: PMC7020780
doi:
Substances chimiques
Biomarkers
0
HAVCR2 protein, human
0
Hepatitis A Virus Cellular Receptor 2
0
IL2RA protein, human
0
Interleukin-2 Receptor alpha Subunit
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3158Informations de copyright
Copyright © 2020 Leotta, Sapienza, Camuglia, Avola, Marco, Moschetti, Curto Pelle, Markovic, Milone, Cupri, Bianco, Frontini, Spadaro, Marchese, Crocchiolo and Milone.
Références
J Hematother Stem Cell Res. 2000 Jun;9(3):393-400
pubmed: 10894361
Bone Marrow Transplant. 1998 Jan;21(1):29-32
pubmed: 9486491
Int J Hematol. 2011 May;93(5):571-577
pubmed: 21384095
J Clin Pathol. 2017 Oct;70(10):886-890
pubmed: 28450387
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Blood. 2018 Jun 21;131(25):2846-2855
pubmed: 29545329
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
N Engl J Med. 2013 Aug 8;369(6):529-39
pubmed: 23924003
Blood. 2011 Aug 11;118(6):1685-92
pubmed: 21636856
Transpl Immunol. 2017 Aug;43-44:27-32
pubmed: 28687251
Leuk Lymphoma. 2000 Aug;38(5-6):533-40
pubmed: 10953974
Blood. 2018 May 17;131(20):2193-2204
pubmed: 29622549
Blood. 2009 Jan 8;113(2):273-8
pubmed: 18832652
Bone Marrow Transplant. 1998 Apr;21(8):769-73
pubmed: 9603399
Blood. 2015 Jan 1;125(1):199-205
pubmed: 25377785
Biol Blood Marrow Transplant. 2013 Sep;19(9):1323-30
pubmed: 23791624
Exp Hematol. 2003 Nov;31(11):1044-50
pubmed: 14585368
Biol Blood Marrow Transplant. 2013 Jan;19(1):22-7
pubmed: 23041600
J Allergy Clin Immunol. 2000 Jul;106(1 Pt 2):S45-50
pubmed: 10887333
Bone Marrow Transplant. 2013 Sep;48(9):1230-6
pubmed: 23584443
Bone Marrow Transplant. 2009 Dec;44(11):729-37
pubmed: 19398965
Blood. 2015 Jul 2;126(1):113-20
pubmed: 25987657
Lancet Haematol. 2015 Jan;2(1):e21-9
pubmed: 26687425
JCI Insight. 2017 Feb 9;2(3):e89798
pubmed: 28194439
Biol Blood Marrow Transplant. 2015 May;21(5):873-80
pubmed: 25623931
Exp Hematol. 2015 Jun;43(6):430-8.e1
pubmed: 25704053
Bone Marrow Transplant. 2001 Dec;28(12):1093-6
pubmed: 11803348